Massimo Guidoboni

Associate Professor of Oncology

University of Ferrara

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Massimo Guidoboni is an Associate Professor of Oncology at the University of Ferrara, Italy. His research areas include immunotherapy and targeted therapy for metastatic melanoma, with a focus on BRAF V600 mutations and long-term patient outcomes. Recent articles have explored various treatment strategies, including the use of dendritic cell vaccines and the clinical management of advanced cutaneous melanoma.

Articles (10)

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (3)

Ana Arance

University of Barcelona

SPAIN

View details

Maria Grazia Vitale

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

Helen Gogas

Head, Professor in Medical Oncology,

National and Kapodistrian University of Athens

GREECE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Massimo Guidoboni

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

Changes in AXL and/or MITF melanoma subpopulations in patients receiving immunotherapy

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

Stability Program in Dendritic Cell Vaccines: A “Real-World” Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.

Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy).

Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma.

Real Life Clinical Management and Survival in Advanced Cutaneous Melanoma: The Italian Clinical National Melanoma Registry Experience.

Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases.

Melanoma metastasis mimicking gastric cancer: a challenge that starts from diagnosis.

Collaborators (3)

Ana Arance

Maria Grazia Vitale

Helen Gogas

Make your next move.